Abstract: v-raf murine sarcoma viral oncogene homolog B1(BRAF) mutation represents the most common oncogenic event in papillary thyroid cancer(PTC). The value of BRAF mutation in the diagnosis and guiding treatment of PTC has achieved enthusiastic investigation since the initiation and progression of PTC has been correlated with BRAF mutation. However, existing evidence does not suggest BRAF mutation as an independent factor in guiding surgical approach, stratifying recurrence risk, or selecting postoperative radioiodine therapy for PTC patients. Although sorafenib and selumetinib have effectively improved the prognosis of patients with radioactive iodine-refractory PTC, such efficacy is independent of BRAF mutation status